BRUKINSA partnership to increase CLL treatment access BeOne Medicines Ltd., BeOne Care Foundation and The Max Foundation have renewed their partnership until 2028. The collaboration will enhance access to BRUKINSA® (zanubrutinib) for people with chronic lymphocytic leukemia (CLL). The new program is designed to serve approximately 1,000 total patients by 2028. The organizations first began their partnership in 2023. Since then, the program has helped more than 300 patients get access to BRUKINSA.
The initiative is presently offered to patients in Armenia, Ethiopia and Nepal. It has also surpassed its original target by some 150 patients. This has resulted in more patients being treated with cutting-edge cancer care. Many had previously had little or no treatment in their own countries. The new partnership reflects the organizations’ shared commitment to improving access to cancer treatment. It also targets underserved communities in low- and middle-income countries.
The Max Foundation brings experience in implementing oncology access programs. Meanwhile, BeOne Medicines provides donated BRUKINSA for eligible patients. Additionally, the BeOne Care Foundation has committed a $1 million grant. The funding will support patient care, physician engagement, and operational infrastructure. These efforts will continue during the next two years. Together, the organizations aim to strengthen access to essential cancer treatment and related support.
Pat Garcia-Gonzalez, Co-Founder and CEO, The Max Foundation, said “We are thrilled to extend our collaboration with BeOne and the BeOne Care Foundation and further expand access to innovative treatment for people living with CLL in low- and middle-income countries. Working hand in hand with our partner physicians in Armenia, Ethiopia and Nepal we have been able to help hundreds of patients access treatment, enabling many of them to continue to support their families, spend time with loved ones and participate in their communities. We welcome BeOne Medicines and the BeOne Care Foundation’s shared commitment to expanding access to CLL treatment to more countries, patients and families, bringing dignity and hope to those in need.”
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne Medicines, said “From the beginning, our goal has been to ensure that where a person lives does not determine whether they can access high-quality cancer care. Renewing this partnership with The Max Foundation reflects both the impact we have already achieved together and our commitment to reaching many more patients who otherwise may have limited treatment options.”
Christine Riley Miller, President, BeOne Care Foundation, said “The BeOne Care Foundation was established to help eliminate barriers to accessible cancer care in underserved communities. By investing in partners like The Max Foundation, we can help expand access to transformational medicines and strengthen the support systems patients need to achieve the best possible outcomes.”
Target for Expansion: New Countries & 1,000 Patients
The renewed agreement will keep on supporting patients in Armenia, Ethiopia and Nepal through 2028. But the program could also spread to other countries. Other countries that may become eligible are Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo and Zambia. Growth will be driven by operational readiness and shifting access priorities. If implemented, these efforts could provide access to the program for the first time to patients in those countries. The expansion also shows what is possible with a partnership model.
The program is expected to support about 1,000 patients cumulatively by 2028. Therefore, the initiative could provide a scalable approach to improving access to global cancer treatment. The organizations also plan to provide continuity of care for enrolled patients. Following the end of the partnership period, patients will continue to receive treatment when clinically indicated. This strategy is designed to prevent interruptions in treatment. It also benefits the patients who need ongoing care after the current partnership period ends.
Hurdles to Overcome for Novel Cancer Therapies
The most common adult leukemia is CLL (chronic lymphocytic leukemia). It accounts for about one-third of new cases of leukemia worldwide. Approximately 191,000 new cases of CLL are diagnosed each year worldwide. But treatment access remains uneven across different regions.
Many low- and middle-income countries have substantial obstacles to patients accessing innovative cancer therapies. These barriers include limited availability of treatment and difficulties with the healthcare infrastructure.
The revamped BRUKINSA access program is intended to tackle some of these challenges. It provides a mix of medicine donations, financial support, physician engagement and operational resources. Also, the partnership combines organizations with complementary expertise. Max Foundation is an implementer of an oncology access program.
BRUKINSA is a treatment option available through BeOne Medicines to qualifying patients. BeOne Care Foundation offers financial support through its grant. All of these contributions can work together to improve the delivery of cancer treatment. They can also help healthcare teams support patients through their treatment journey.
The expanded partnership through 2028 is another step to increase access to innovative oncology care. It also demonstrates the organizations’ focus on underserved patient populations.
With additional countries under consideration by the program, the initiative could reach more patients with CLL. In the end, the renewed cooperation is to provide quality cancer treatment closer to home.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
